Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2018 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma to Participate in Upcoming Investor Conferences

MALVERN, Pa., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
September 05, 2018 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018

MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
September 04, 2018 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Provides Regulatory Update for IV Meloxicam

MALVERN, Pa., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
August 07, 2018 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Reports Second Quarter 2018 Financial Results

MALVERN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
July 31, 2018 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018

MALVERN, Pa., July 31, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
June 26, 2018 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Announces Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal

MALVERN, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
May 24, 2018 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Receives Complete Response Letter from the FDA

MALVERN, Penn., May 24, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
May 09, 2018 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Reports First Quarter 2018 Financial Results

Upcoming May 26, 2018 PDUFA Date for IV Meloxicam Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., May 09, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue...
May 07, 2018 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam

MALVERN, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
May 02, 2018 16:05 ET | Source: Recro Pharma, Inc.

Recro Pharma Announces Commercial Team Additions

MALVERN, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...